Qiagen has been awarded US Patent No. 7,683,035, "Method of stabilizing and/or isolating nucleic acids."
Inventors listed on the patent are Christoph Erbacher, Helge Bastian, Ralf Wyrich, Uwe Oelmuller, and Thomas Manz.
According to its abstract, the patent relates to a method of stabilizing and/or isolating nucleic acids, wherein a biological sample containing nucleic acids is contacted with a cationic compound. The patent also relates to the cationic compound and its use in stabilizing and/or isolating nucleic acids. Furthermore, the patent relates to pharmaceutical compositions, diagnostic compositions, and compositions used in research, which include cationic compounds or a complex being formed upon contact of said cationic compound with a nucleic acid.
Becton Dickinson has been awarded US Patent No. 7,687,027, "Cleaning compositions, methods, and materials for reducing nucleic acid contamination."
Eric McGill is the sole inventors listed on the patent.
According to its abstract, the patent relates to methods using cleaning compositions for the reduction of nucleic acid contamination. In particular, the patent covers cationic compositions that bind to, and can remove, extraneous nucleic acids, polynucleotides, and DNA from the surface of a substrate. Preferably, the cationic compositions include a substance with a molecular weight of 500 Da or more. The invention can be used as a surface decontamination agent in PCR and other related DNA amplification techniques.
Life Technologies has been awarded US Patent No. 7,687,247, "Process for controlling contamination of nucleic acid amplification reactions."
Inventors listed on the patent are James Hartley and Mark Berninger.
According to its abstract, the patent relates to a method of incorporating an exo-sample nucleotide into the amplified product strands resulting from a nucleic acid amplification process. Once the product strands have been obtained and analyzed — for example by hybridization, Southern blot, et cetera — the exo-sample strands can be selectively destroyed by acting on the incorporated exo-sample nucleotide. In a first embodiment of the invention, the exo-sample nucleotide is incorporated by carrying out the amplification to reaction in the presence of an excess of exo-sample nucleotide tri-phosphate. In a second embodiment, the exo-sample nucleotide is incorporated by carrying out the amplification reaction in the presence of an oligonucleotide which has, as part of its sequence, one or more exo-sample nucleotides.
Roche Diagnostics has been awarded US Patent No. 7,687,260, "Imaging fluorescence signals using telecentric optics."
Martin Gutekunst is the sole inventor listed on the patent.
According to its abstract, the patent relates to the field of DNA analysis, and more particularly, describes a device for the parallel imaging of fluorescence intensities at a plurality of sites as a measure for DNA hybridization. The invention is directed to a device to image multiplex real time PCR or to read out DNA microarrays, according to the patent's abstract.